
Sign up to save your podcasts
Or


A week after the federal government moved to ease access to six peptides, NBC Bay Area reported on a breast cancer survivor whose cancer came back after she used an injectable peptide "Glow Stack" bought through a med spa. Dr. Tom McCann, a board-certified diagnostic radiologist, and Nova, his AI co-host, cover whether one case can show cause, why scientists worry about growth-promoting peptides and cancer, what the October 28 HHS policy does and does not do, who should avoid these products, and what to do if you already use BPC-157.
Key facts. NBC Bay Area reported no conclusive evidence that BPC-157 contributed to the recurrence and called the link theoretical (Nov 5, 2026). The HHS policy is interim enforcement discretion for BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon: not FDA approval and not an addition to the compounding bulks list; comments closed Nov 13, and as of mid-November no final action had been reported (Holland & Knight; Venable). AP reported that FDA scientists opposed it (Oct 28, 2026). In lab and animal work, BPC-157 increased VEGFR2 and new vessel growth (Hsieh 2017). Thymosin beta-4 has been linked to tumor spread (Xiao 2012); Epitalon raised telomerase in cell culture (Khavinson 2003). Higher natural IGF-1 was linked to modestly higher breast cancer risk in a pooled analysis (2010). Human safety data for these peptides are minimal (Poolton 2026; Vasylieva 2026; Moiz 2026). BPC-157 and the other peptides discussed are not FDA approved.
Disclosure. Dr. McCann performs aesthetic injections at Artemis Modern Aesthetics. No company paid for this episode.
For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback. For clinicians: courses and imaging teaching at mccannmd.com.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. NBC Bay Area, Nov 5, 2026. https://www.nbcbayarea.com/investigations/santa-cruz-woman-cancer-unapproved-peptides/4171354/
2. AP via News4Jax, Oct 28, 2026. https://www.news4jax.com/business/2026/10/28/fda-scientists-opposed-the-trump-administrations-effort-to-ease-peptides-access/
3. Holland & Knight, Nov 4, 2026. https://www.hklaw.com/en/insights/publications/2026/11/hhs-issues-interim-enforcement-discretion-policy-for-compounding
4. Venable, Nov 6, 2026. https://www.venable.com/insights/publications/2026/11/hhs-announces-interim-enforcement-discretion
5. Hsieh MJ, et al. J Mol Med. 2017;95(3):323-333. https://doi.org/10.1007/s00109-016-1488-y
6. Xiao Y, et al. Crit Rev Eukaryot Gene Expr. 2012;22(2):109-116. https://doi.org/10.1615/critreveukargeneexpr.v22.i2.30
7. Khavinson VKh, et al. Bull Exp Biol Med. 2003;135(6):590-592. https://doi.org/10.1023/a:1025493705728
8. Key TJ, et al. Lancet Oncol. 2010;11(6):530-542. https://doi.org/10.1016/S1470-2045(10)70095-4
9. Vasylieva V, et al. Sex Med Rev. 2026;14(4). https://doi.org/10.1093/sxmrev/qeag078
10. Moiz A, et al. Mo Med. 2026;123(4):337-343. https://pubmed.ncbi.nlm.nih.gov/42757290/
11. Poolton JT, et al. Acta Orthop Belg. 2026;92(3). https://doi.org/10.52628/92.3.15837
Can filler replace a facelift? Sometimes, and sometimes it makes things worse. Dr. Tom McCann, a board-certified diagnostic radiologist, and Nova, his AI co-host, walk through how a face ages in five layers (bone, deep fat, ligaments and the SMAS, superficial fat, skin), what fillers, neuromodulators and biostimulators can and cannot do, why chasing sagging with syringes leads to facial overfilled syndrome, and how to sort yourself into the injectable, combination or surgical group.
Key facts. The facial skeleton resorbs with age at the orbits, maxilla and prejowl (Mendelson and Wong 2012). Filler can still be visible on MRI years after the last injection (Master 2024). OnabotulinumtoxinA was FDA approved in October 2024 for moderate to severe platysma bands; it treats muscle pull, not loose skin. Upper eyelid heaviness can be extra skin, a low brow, true lid ptosis or fat, and only a small part of that responds to injection. Functional signs for upper lid surgery include MRD1 of 2 mm or less and measurable upper visual field loss (AAO 2011). Tear trough filler suits a hollow groove with good skin and no bags or puffiness; bags, loose skin and lid laxity point to lower blepharoplasty. Focused ultrasound gives small, real tightening with no good data past one year; thread lifts show limited durability (systematic review 2018). Deep plane facelift hematoma rate about 2.7%, major about 1% (meta-analysis 2026).
Tom's five checks: the pinch (hanging skin), the lift (push cheek and jowl up and back), lying down versus standing photos, the smile (how existing filler moves), and the eyes (skin, brow, lid margin or fat). This is Tom's practical framework, not a validated scale.
Picking a surgeon: board certification matched to the operation, real volume of that exact procedure, photos of similar patients at a year or more, an accredited facility, and a clear plan for complications.
Disclosure. Dr. McCann performs injectables and energy-based device treatments at Artemis Modern Aesthetics. He does not perform facelifts or eyelid surgery. No company paid for this episode.
For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback. For clinicians: courses and imaging teaching at mccannmd.com.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. Mendelson B, Wong CH. Changes in the facial skeleton with aging: implications and clinical applications in facial rejuvenation. Aesthetic Plast Surg. 2012;36(4):753-760. https://doi.org/10.1007/s00266-012-9904-3
2. Shaw RB Jr, Katzel EB, Koltz PF, et al. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg. 2011;127(1):374-383. https://doi.org/10.1097/PRS.0b013e3181f95b2d
3. Wong CH, Mendelson B. Newer understanding of specific anatomic targets in the aging face as applied to injectables: aging changes in the craniofacial skeleton and facial ligaments. Plast Reconstr Surg. 2015;136(5 Suppl):44S-48S. https://doi.org/10.1097/PRS.0000000000001752
4. Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007;119(7):2219-2227. https://doi.org/10.1097/01.prs.0000265403.66886.54
5. Mendelson BC, Muzaffar AR, Adams WP Jr. Surgical anatomy of the midcheek and malar mounds. Plast Reconstr Surg. 2002;110(3):885-896. https://doi.org/10.1097/00006534-200209010-00026
6. Mitz V, Peyronie M. The superficial musculo-aponeurotic system (SMAS) in the parotid and cheek area. Plast Reconstr Surg. 1976;58(1):80-88. https://doi.org/10.1097/00006534-197607000-00013
7. Sundaram H, Liew S, Signorini M, et al. Global Aesthetics Consensus: hyaluronic acid fillers and botulinum toxin type A, recommendations for combined treatment and optimizing outcomes in diverse patient populations. Plast Reconstr Surg. 2016;137(5):1410-1423. https://doi.org/10.1097/PRS.0000000000002119
8. Lim TS, et al. Facial overfilled syndrome. Dermatol Clin. 2024;42(1). https://doi.org/10.1016/j.det.2023.06.007
9. Cotofana S, Gotkin RH, Frank K, et al. Anatomy behind the facial overfilled syndrome: the transverse facial septum. Dermatol Surg. 2020;46(8). https://doi.org/10.1097/DSS.0000000000002236
10. Master M, Azizeddin A, Master V. Hyaluronic acid filler longevity in the mid-face: a review of 33 magnetic resonance imaging studies. Plast Reconstr Surg Glob Open. 2024;12(7):e5934. https://doi.org/10.1097/GOX.0000000000005934
11. Chang JR, Baharestani S, Salek SS, et al. Delayed superficial migration of retained hyaluronic acid years following periocular injection. Ophthalmic Plast Reconstr Surg. 2017;33(3S). https://doi.org/10.1097/IOP.0000000000000434
12. Fabi S, Humphrey S, Biesman B, et al. Improvement of platysma prominence with onabotulinumtoxinA: safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025;92(2). https://doi.org/10.1016/j.jaad.2024.10.027
13. Shridharani SM, Ogilvie P, Couvillion M, et al. Improving neck and jawline aesthetics with onabotulinumtoxinA by minimizing platysma muscle contraction effects: phase 3 randomized, placebo-controlled study. Aesthet Surg J. 2025. https://doi.org/10.1093/asj/sjae220
14. AbbVie. BOTOX Cosmetic (onabotulinumtoxinA) receives FDA approval for moderate to severe vertical bands connecting the jaw and neck (platysma bands). Press release, October 18, 2024. https://news.abbvie.com/2024-10-18-BOTOX-R-Cosmetic-onabotulinumtoxinA-Receives-FDA-Approval-for-Moderate-to-Severe-Vertical-Bands-Connecting-the-Jaw-and-Neck-Platysma-Bands
15. Cahill KV, Bradley EA, Meyer DR, et al. Functional indications for upper eyelid ptosis and blepharoplasty surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2011;118(12):2510-2517. https://doi.org/10.1016/j.ophtha.2011.09.029
16. Kim KK, Granick MS, Baum GA, et al. American Society of Plastic Surgeons evidence-based clinical practice guideline: eyelid surgery for upper visual field improv...
On November 9, 2026, the FDA required every GLP-1 drug, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about NAION, a rare optic nerve stroke that can cause sudden, painless and often permanent vision loss in one eye. Dr. Tom McCann, a board-certified diagnostic radiologist, and Nova, his AI co-host, walk through what NAION is, the 2024 study that raised the alarm, the larger studies that did and did not confirm it, what European and US regulators concluded, the separate issue of diabetic retinopathy, who should be most careful, and what to do if your vision changes.
Key facts. The FDA describes a potential increased risk of rare NAION events with GLP-1 receptor agonists and added it to Warnings and Precautions for the whole class; in its pool of 126 randomized trials there were 10 probable cases on GLP-1 drugs and 5 on placebo (FDA, Nov 9, 2026). Europe's regulator classed NAION as a very rare side effect of semaglutide, up to 1 in 10,000 users, about one extra case per 10,000 person-years (EMA, Jun 2025). Observational studies in type 2 diabetes mostly show roughly a doubling of relative risk, with low certainty and a low absolute risk; findings in people taking semaglutide for weight loss are inconsistent. Causality has not been established. In SUSTAIN-6, retinopathy complications were more common on semaglutide; the dedicated FOCUS trial has not reported.
If you have sudden vision loss in one eye, get a same-day eye evaluation. Do not stop a prescribed medication without talking to your prescriber.
Disclosure. Dr. McCann performs aesthetic treatments at Artemis Modern Aesthetics, which runs a medically supervised weight loss program. No company paid for this episode.
For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback. For clinicians: courses and imaging teaching at mccannmd.com.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. U.S. Food and Drug Administration. FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. Drug Safety Communication, Nov 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
2. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. Jun 6, 2025. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
3. World Health Organization. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION). Jun 27, 2025. https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion
4. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. https://doi.org/10.1001/jamaophthalmol.2024.2296
5. Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study. Diabetes Obes Metab. 2025;27(6). https://doi.org/10.1111/dom.16316
6. Grauslund J, Taha AA, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97. https://doi.org/10.1186/s40942-024-00620-x
7. Cai CX, Hribar M, Baxter S, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025;143(4). https://doi.org/10.1001/jamaophthalmol.2024.6555
8. Abbass NJ, Nahlawi R, Shaia JK, et al. The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2025;274. https://doi.org/10.1016/j.ajo.2025.02.025
9. Chou CC, Pan SY, Sheen YJ, et al. Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study. Ophthalmology. 2025;132(4). https://doi.org/10.1016/j.ophtha.2024.10.030
10. Hsu AY, Kuo HT, Wang YH, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes. JAMA Ophthalmol. 2025;143(5). https://doi.org/10.1001/jamaophthalmol.2025.0349
11. Chrzanowski J, Walicka M, Burzynski J, et al. Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. PLoS Med. 2026. https://doi.org/10.1371/journal.pmed.1005064
12. Abdelaal A, Abu Serhan H, Alsaadi M, et al. Semaglutide and the risk of nonarteritic ischemic optic neuropathy: a systematic review and certainty of evidence meta-analysis. Ophthalmology. 2026. https://doi.org/10.1016/j.ophtha.2026.02.013
13. Natividade GR, Spiazzi BF, Baumgarten MW, et al. Ocular adverse events with semaglutide: a systematic review and meta-analysis. JAMA Ophthalmol. 2025;143(9). https://doi.org/10.1001/jamaophthalmol.2025.2489
14. Wang L, et al. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327. https://doi.org/10.1001/jamanetworkopen.2025.26327
15. Hong et al. Ocular outcomes with tirzepatide versus glucagon-like peptide-1 receptor agonists in type 2 diabetes. Ophthalmol Retina. 2026. https://doi.org/10.1016/j.oret.2026.02.002
16. Katz BJ, et al. Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide. JAMA Ophthalmol. 2025. https://doi.org/10.1001/jamaophthalmol.2024.6058
17. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141
18. Malluhi et al. GLP-1 receptor agonists and ocular safety: pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk. Biomol Biomed. 2026. https://doi.org/10.17305/bb.2026.14701
19. ClinicalTrials.gov. FOCUS: Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (NCT03811561). Accessed Nov 18, 2026. https://clinicaltrials.gov/study/NCT03811561
20. Amini et al. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association. Acta Ophthalmol. 2025. https://doi.org/10.1111/aos.17473
Red light masks, near-infrared panels and full-body beds promise everything from collagen to fat loss to sharper thinking. Dr. Tom McCann, a board-certified diagnostic radiologist, and Nova, his AI co-host, sort the evidence without naming a single brand. They cover how photobiomodulation works (cytochrome c oxidase in the mitochondria, nitric oxide release, a small signaling burst of reactive oxygen), why the dose response is a curve and not a ramp, which wavelengths matter (red about 630 to 670 nm, near-infrared about 800 to 850 nm, blue about 415 nm for acne), and how to calculate a dose from irradiance and time.
Key facts. Fluence (J/cm2) equals irradiance (W/cm2) times seconds: 30 mW/cm2 for 10 minutes is 18 J/cm2. The strongest evidence is for preventing oral mucositis from cancer treatment, with specific protocols (MASCC/ISOO 2019). There is moderate evidence for male pattern hair loss and some neck and knee pain, mostly with near-infrared lasers. Evidence for skin rejuvenation and acne is modest and low quality. Body contouring, cognition and whole-body wellness claims are weak. Red light aimed into the eye to slow childhood myopia shows efficacy in trials, but devices measured near or above retinal safety limits and retinal damage has been reported. Protect your eyes, especially from invisible near-infrared.
Five questions for any device: wavelengths in nm; irradiance in mW/cm2 at a stated distance, measured as light output; fluence per session in J/cm2; a schedule close to a study that worked; eye protection and clearance for your use.
Disclosure. Dr. McCann performs aesthetic treatments, including some that use light and lasers, at Artemis Modern Aesthetics. No company paid for this episode and no devices or brands are named.
For clinicians: courses and imaging teaching at mccannmd.com.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. Hamblin MR. Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochem Photobiol. 2018;94(2):199-212. https://doi.org/10.1111/php.12864
2. Huang YY, Chen AC, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response. 2009;7(4):358-383. https://doi.org/10.2203/dose-response.09-027.Hamblin
3. Karu TI. Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life. 2010;62(8):607-610. https://pubmed.ncbi.nlm.nih.gov/20681024/
4. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516-533. https://pubmed.ncbi.nlm.nih.gov/22045511/
5. Maghfour J, Ozog DM, Mineroff J, et al. Photobiomodulation CME part I: Overview and mechanism of action. J Am Acad Dermatol. 2024;91(5):793-802. https://doi.org/10.1016/j.jaad.2023.10.073
6. Mineroff J, Maghfour J, Ozog DM, et al. Photobiomodulation CME part II: Clinical applications in dermatology. J Am Acad Dermatol. 2024;91(5):805-815. https://doi.org/10.1016/j.jaad.2023.10.074
7. Maghfour J, Mineroff J, Ozog DM, et al. Evidence-based consensus on the clinical application of photobiomodulation. J Am Acad Dermatol. 2025;93(2):429-443. https://doi.org/10.1016/j.jaad.2025.04.031
8. Grimes DR. Methodological issues in visible LED therapy dermatological research and reporting. PLoS One. 2025;20(10):e0332995. https://doi.org/10.1371/journal.pone.0332995
9. Wunsch A, Matuschka K. A controlled trial to determine the efficacy of red and near-infrared light treatment in patient satisfaction, reduction of fine lines, wrinkles, skin roughness, and intradermal collagen density increase. Photomed Laser Surg. 2014;32(2):93-100. https://doi.org/10.1089/pho.2013.3616
10. Lee SY, Park KH, Choi JW, et al. A prospective, randomized, placebo-controlled, double-blinded, and split-face clinical study on LED phototherapy for skin rejuvenation. J Photochem Photobiol B. 2007;88(1):51-67. https://doi.org/10.1016/j.jphotobiol.2007.04.008
11. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br J Dermatol. 2000;142(5):973-978. https://doi.org/10.1046/j.1365-2133.2000.03481.x
12. Barbaric J, Abbott R, Posadzki P, et al. Light therapies for acne. Cochrane Database Syst Rev. 2016;9:CD007917. https://doi.org/10.1002/14651858.CD007917.pub2
13. Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines (MASCC/ISOO). Support Care Cancer. 2019;27(10):3969-3983. https://doi.org/10.1007/s00520-019-04890-2
14. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141. https://doi.org/10.1016/j.jaad.2017.02.054
15. Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis. Lancet. 2009;374(9705):1897-1908. https://doi.org/10.1016/S0140-6736(09)61522-1
16. Stausholm MB, Naterstad IF, Joensen J, et al. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis. BMJ Open. 2019;9(10):e031142. https://doi.org/10.1136/bmjopen-2019-031142
17. Mendes-Costa LDS, et al. Photobiomodulation: systematic review and meta-analysis of the most used parameters in the resolution of diabetic foot ulcers. Lasers Med Sci. 2021;36(6):1129-1138. https://doi.org/10.1007/s10103-020-03192-y
18. Jackson RF, Dedo DD, Roche GC, et al. Low-level laser therapy as a non-invasive approach for body contouring: a randomized, controlled study. Lasers Surg Med. 2009;41(10):799-809. https://doi.org/10.1002/lsm.20855
19. Lee TL, Ding Z, Chan AS. Can transcranial photobiomodulation improve cognitive function? A systematic review of human studies. Ageing Res Rev. 2023;83:101786. https://doi.org/10.1016/j.arr.2022.101786
20. Hacke W, Schellinger PD, Albers GW, et al. Transcranial laser therapy in acute stroke treatment: results of NEST-3. Stroke. 2014;45(11):3187-3193. https://doi.org/10.1161/STROKEAHA.114...
What people notice in a face is light and shadow, not millimeters. Dr. Tom McCann, a board-certified diagnostic radiologist, and Nova, his AI co-host, walk through LightFrame™, the consultation method Tom built at Artemis Modern Aesthetics. They cover why the same under-eye shadow can need opposite plans, the five layers LightFrame reads (Frame, Support, Volume, Surface and Light), why it avoids the golden-ratio mask, what happens in the hour-long consult, when ultrasound is used, what you leave with, what it costs, and what the method does not claim.
Key facts. In photo overlays spanning 10 to 50 years, the lid-cheek junction barely moved; it became more visible through contrast and shadow (Lambros 2007). Facial contrast falls with age, and lower-contrast faces are judged older (Porcheron 2013, authors from a skin research center funded by a cosmetics company). CT studies show the orbits enlarge, midface angles flatten and the mandible shortens with age (Shaw 2011). Facial fat sits in separate compartments that age differently (Rohrich and Pessa 2007). The golden-ratio Phi mask has been criticized for fitting many faces poorly (Holland 2008). Ultrasound can often show where old filler sits (Schelke 2010).
The LightFrame™ consult is $250, credited in full toward treatment booked within 30 days. Every consult and treatment is done by Dr. McCann. LightFrame™ is a consultation and planning method, not a validated scoring test, and it cannot promise a result.
Disclosure. LightFrame™ is Tom's own method and trademark, and the consult is a paid service at Artemis. This episode is about something he sells. No outside company paid for it.
For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback. Read more at mccannmd.com/lightframe. For clinicians: courses and imaging teaching at mccannmd.com.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. Lambros V. Observations on periorbital and midface aging. Plast Reconstr Surg. 2007;120(5):1367-1376. https://doi.org/10.1097/01.prs.0000279348.09156.c3
2. Porcheron A, Mauger E, Russell R. Aspects of facial contrast decrease with age and are cues for age perception. PLoS One. 2013;8(3):e57985. https://doi.org/10.1371/journal.pone.0057985
3. Shaw RB Jr, Katzel EB, Koltz PF, et al. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg. 2011;127(1):374-383. https://doi.org/10.1097/PRS.0b013e3181f95b2d
4. Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007;119(7):2219-2227. https://doi.org/10.1097/01.prs.0000265403.66886.54
5. Holland E. Marquardt's Phi mask: pitfalls of relying on fashion models and the golden ratio to describe a beautiful face. Aesthetic Plast Surg. 2008;32(2):200-208. https://doi.org/10.1007/s00266-007-9080-z
6. Schelke LW, Van Den Elzen HJ, Erkamp PP, Neumann HA. Use of ultrasound to provide overall information on facial fillers and surrounding tissue. Dermatol Surg. 2010;36 Suppl 3:1843-1851. https://doi.org/10.1111/j.1524-4725.2010.01740.x
One of our technologists asked what in the drugstore skincare aisle is actually supported by evidence. Dr. Tom McCann and Nova, his AI co-host, grade the common ingredients into strong, moderate and weak tiers, explain what niacinamide, vitamin C, alpha hydroxy acids, azelaic acid, hyaluronic acid, ceramides, peptides, growth factors and collagen supplements have and haven't shown, and take apart label claims like dermatologist recommended, hypoallergenic and boosts collagen.
Key facts. Topical 5% niacinamide improved fine lines, red blotchiness, spots and sallowness in 50 women over 12 weeks (Bissett 2005, manufacturer-run). Oral nicotinamide 500 mg twice daily lowered new non-melanoma skin cancers by 23% in 386 high-risk patients (ONTRAC, NEJM 2015). 8% glycolic or lactic acid improved photodamage in 76% and 71% of women vs 40% on vehicle (Stiller 1996). 20% azelaic acid matched 4% hydroquinone for melasma in 329 women (1991). Cochrane 2017 (77 trials): moisturizers reduce eczema flares, no moisturizer shown better than another. BEEP 2020 (1,394 infants): daily emollient did not prevent eczema. Collagen supplements: no benefit in non-industry-funded or high-quality trials (Am J Med 2025, 23 RCTs). Of 174 best-selling moisturizers, 12% were free of common allergens; 45% of fragrance-free products had a fragrance cross-reactor or botanical (JAMA Dermatol 2017).
Disclosure. No brands are named, nobody paid for this episode, and industry-funded studies are identified as such. Tom's practice, Artemis Modern Aesthetics, sells skincare in the office.
For clinicians: courses, the Complication and Emergency Protocol Pack, and imaging teaching at mccannmd.com. For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med. 2013;158(11):781-790. https://doi.org/10.7326/0003-4819-158-11-201306040-00002
2. Bissett DL, Oblong JE, Berge CA. Niacinamide: a B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005;31(7 Pt 2):860-865. https://doi.org/10.1111/j.1524-4725.2005.31732
3. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618-1626. https://doi.org/10.1056/NEJMoa1506197
4. Humbert PG, Haftek M, Creidi P, et al. Topical ascorbic acid on photoaged skin: clinical, topographical and ultrastructural evaluation. Exp Dermatol. 2003;12(3):237-244. https://doi.org/10.1034/j.1600-0625.2003.00008.x
5. Stiller MJ, Bartolone J, Stern R, et al. Topical 8% glycolic acid and 8% L-lactic acid creams for the treatment of photodamaged skin. Arch Dermatol. 1996;132(6):631-636. PMID 8651713. https://pubmed.ncbi.nlm.nih.gov/8651713/
6. Balina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30(12):893-895. https://doi.org/10.1111/j.1365-4362.1991.tb04362.x
7. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. https://doi.org/10.1016/j.jaad.2023.12.017
8. Pavicic T, Gauglitz GG, Lersch P, et al. Efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment. J Drugs Dermatol. 2011;10(9):990-1000. PMID 22052267. https://pubmed.ncbi.nlm.nih.gov/22052267/
9. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:CD012119. https://doi.org/10.1002/14651858.CD012119.pub2
10. Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020;395(10228):962-972. https://doi.org/10.1016/S0140-6736(19)32984-8
11. Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. https://doi.org/10.1111/j.1467-2494.2005.00261.x
12. Abud B, McGinn L, Cawthon E, et al. A randomized, double-blinded pilot study comparing synthetic versus human-derived topical epidermal growth factor for facial rejuvenation. J Cosmet Dermatol. 2026;25(5):e70927. https://doi.org/10.1111/jocd.70927
13. Myung SK, Park Y. Effects of collagen supplements on skin aging: a systematic review and meta-analysis of randomized controlled trials. Am J Med. 2025;138(9):1264-1277. https://doi.org/10.1016/j.amjmed.2025.04.034
14. Xu S, Kwa M, Lohman ME, Evers-Meltzer R, Silverberg JI. Consumer preferences, product characteristics, and potentially allergenic ingredients in best-selling moisturizers. JAMA Dermatol. 2017;153(11):1099-1105. https://doi.org/10.1001/jamadermatol.2017.3046
15. US Food and Drug Administration. Alpha hydroxy acids (content current as of November 22, 2022). https://www.fda.gov/cosmetics/cosmetic-ingredients/alpha-hydroxy-acids
16. US Food and Drug Administration. FDA works to protect consumers from potentially harmful OTC skin lightening products, April 19, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-protect-consumers-potentially-harmful-otc-skin-lightening-products
17. US Food and Drug Administration. Hypoallergenic cosmetics. https://www.fda.gov/cosmetics/cosmetics-labeling-claims/hypoallergenic-cosmetics
18. US Food and Drug Administration. Wrinkle treatments and other anti-aging products. https://www.fda.gov/cosmetics/products/wrinkle-treatments-and-other-anti-aging-products
19. US Food and Drug Administration. FDA expands sunscreen options for the first time in 20 years, June 9, 2026. https://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years
20. US Food and Drug Administration. Limited number of voluntary recalls initiated after FDA testing of acne products for benzene, March 11, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/limited-number-voluntary-recalls-initiated-after-fda-testing-acne-products-benzene-findings-show
Whole-body MRI is getting cheaper and easier to book. Dr. Tom McCann, a board-certified diagnostic radiologist who reads whole-body screening MRIs, and Nova, his AI co-host, go through the latest news: a nationwide rollout of whole-body MRI packages and a company-funded model claiming the scans can pay for themselves for employers. They cover what the scan does and doesn't see, what the American College of Radiology, a 2026 AJR expert panel and a new Cochrane protocol say about the evidence, how often healthy people get a finding that needs more testing, and five questions to ask before you book.
Key facts. Fitnescity Health is offering non-contrast whole-body MRI at nearly 100 US locations, $995 to $2,995, and says it does not replace mammography or colorectal screening (AuntMinnie, Nov 10, 2026). A Prenuvo-released model of a hypothetical 100,000-worker employer estimated about 41 cents recovered per dollar when everyone was scanned once and $1.22 in a higher-risk group aged 50 and over (Nov 12, 2026). ACR: insufficient evidence to recommend total body MRI screening in people without symptoms or risk factors (2023). In 12 studies of 5,373 people without symptoms, 32.1% had a critical or indeterminate finding and about 16% of findings were false positives (JMRI 2019). Cochrane began a formal review of whole-body MRI and CT screening in 2026; results are not yet published.
For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback. For clinicians: courses and imaging teaching at mccannmd.com.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. AuntMinnie.com staff. Fitnescity Health adds whole-body MRI to preventive imaging network. November 10, 2026. https://www.auntminnie.com/clinical-news/mri/news/16425072/fitnescity-health-adds-wholebody-mri-to-preventive-imaging-network
2. Prenuvo (PR Newswire). New Prenuvo research finds whole-body MRI screening could pay for itself for employers. November 12, 2026. https://www.prnewswire.com/news-releases/new-prenuvo-research-finds-whole-body-mri-screening-could-pay-for-itself-for-employers-302937066.html
3. American College of Radiology. ACR statement on screening total body MRI. April 17, 2023. https://www.acr.org/News-and-Publications/Media-Center/2023/ACR-Statement-on-Screening-Total-Body-MRI
4. Petralia G, Akin O, Brookmeyer C, et al. Whole-body MRI in asymptomatic individuals: promise and perils. Expert panel review. AJR Am J Roentgenol. Published online September 23, 2026. https://doi.org/10.2214/AJR.26.35420
5. Chen Z, Johansson M, Albarqouni L, Woloshin S, Jørgensen KJ. Whole-body MRI or CT screening for reducing morbidity and mortality from multiple diseases in asymptomatic adults (protocol). Cochrane Database Syst Rev. 2026;8:CD016234. https://doi.org/10.1002/14651858.CD016234
6. Lee J, Cyphers E, Beutler BD. Brief communication: the clinical opportunities and ongoing challenges with whole-body MRI for screening. Clin Imaging. 2026;138:110907. https://doi.org/10.1016/j.clinimag.2026.110907
7. Kwee RM, Kwee TC. Whole-body MRI for preventive health screening: a systematic review of the literature. J Magn Reson Imaging. 2019;50(5):1489-1503. https://doi.org/10.1002/jmri.26736
8. Umipig K. Prenuvo opens its 200K MRI scans to researchers. Longevity.Technology, October 16, 2026. https://longevity.technology/news/prenuvo-opens-its-200k-mri-scans-to-researchers/
9. Madden Yee K. Road to RSNA 2026: MRI preview. AuntMinnie.com, November 12, 2026. https://www.auntminnie.com/resources/conference/rsna/2026/mri-preview/article/16425347/road-to-rsna-2026-mri-preview
Is your phone aging your skin? Dr. Tom McCann, a board-certified diagnostic radiologist, and Nova, his AI co-host, compare three kinds of light: sunlight, the blue light from screens, and the radiation from medical imaging. They cover what blue light is, why the sun delivers far more of it than any device, what a 2022 systematic review found about screens and skin, why visible light matters for pigment in darker skin and melasma, what iron oxide in tinted sunscreen does, what SPF and broad spectrum do and don't cover, and why routine X-rays and CT scans are nowhere near the doses that affect skin.
Key facts. Blue light is about 25% of the sun's rays and about 30% of what electronic devices emit, but the sun is the main source of effective exposure for pigmentation and oxidative stress (J Photochem Photobiol B 2022). Of 87 articles on device blue light and skin, 9 met inclusion criteria; device blue light was not identified as a hazard for pigmentation, redness, yellowness or melasma, and was not classified as a photoaging hazard, with low confidence (Photochem Photobiol Sci 2022). Visible light caused darker, longer-lasting pigmentation than UVA1 in skin types IV to VI and none in type II (J Invest Dermatol 2010). In 68 melasma patients on hydroquinone, iron oxide sunscreen gave 15% greater improvement in MASI and 28% in colorimetry than UV-only sunscreen at 8 weeks (Photodermatol Photoimmunol Photomed 2014). Noticeable skin changes after a single procedure appear about a month after a peak skin dose above several gray (Radiology 2010). US average natural background radiation is about 3 mSv a year; a chest X-ray is about 10 days of it, a dental X-ray about 1 day, screening digital mammography about 34 days, a brain CT about 7 months (RadiologyInfo.org).
For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback. For clinicians: courses and imaging teaching at mccannmd.com.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. de Gálvez EN, Aguilera J, Solis A, et al. The potential role of UV and blue light from the sun, artificial lighting, and electronic devices in melanogenesis and oxidative stress. J Photochem Photobiol B. 2022;228:112405. https://doi.org/10.1016/j.jphotobiol.2022.112405
2. Ceresnie MS, Patel J, Lim HW, Kohli I. The cutaneous effects of blue light from electronic devices: a systematic review with health hazard identification. Photochem Photobiol Sci. Published online 2022; 2023;22(2):457-464. https://doi.org/10.1007/s43630-022-00318-9
3. Duteil L, Queille-Roussel C, Lacour JP, Montaudié H, Passeron T. Short-term exposure to blue light emitted by electronic devices does not worsen melasma. J Am Acad Dermatol. 2020;83(3):913-914. https://doi.org/10.1016/j.jaad.2019.12.047
4. Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010;130(8):2092-2097. https://doi.org/10.1038/jid.2010.95
5. Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, Fuentes-Ahumada C, Torres-Álvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed. 2014;30(1):35-42. https://doi.org/10.1111/phpp.12086
6. Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015;72(1):189-190.e1. https://doi.org/10.1016/j.jaad.2014.08.023
7. Polena H, Queille-Roussel C, Graizeau C, Duteil L, Sayag M, Passeron T. Comparison of visible light-protective tinted sunscreen to untinted sunscreen to protect melasma patients during summer: a prospective randomized investigator-blinded study. J Cosmet Dermatol. 2025;24(10):e70450. https://doi.org/10.1111/jocd.70450
8. US Food and Drug Administration. Sunscreen: how to help protect your skin from the sun (content current as of October 16, 2026). https://www.fda.gov/drugs/understanding-over-counter-medicines/sunscreen-how-help-protect-your-skin-sun
9. Balter S, Hopewell JW, Miller DL, Wagner LK, Zelefsky MJ. Fluoroscopically guided interventional procedures: a review of radiation effects on patients' skin and hair. Radiology. 2010;254(2):326-341. https://doi.org/10.1148/radiol.2542082312
10. RadiologyInfo.org (American College of Radiology and Radiological Society of North America). Radiation dose (reviewed April 15, 2025). https://www.radiologyinfo.org/en/info/safety-xray
11. Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med. 2013;158(11):781-790. https://doi.org/10.7326/0003-4819-158-11-201306040-00002
Twenty-somethings are booking toxin to prevent wrinkles. Dr. Tom McCann and Nova, his AI co-host, look at how common it really is, the theory behind prejuvenation, the identical-twin case report it rests on, what a 2025 computer model found, the downsides of starting early, what the label covers, why screening for body dysmorphic disorder matters, and the prevention with the best evidence.
Key facts. ISAPS survey as reported by ABC News: 20.5 million nonsurgical procedures worldwide in 2024, up 44% from 2020. ASPS 2024: 9,883,711 neuromodulator procedures by member surgeons, 142,907 in patients aged 20 to 29. TikTok prejuvenation study: 303 videos, more than 61 million views, 84.8% posted by nonphysicians (Rothchild 2024). Identical twins: no imprinted forehead or glabellar lines in the twin treated 2 to 3 times a year for 13 years (Binder 2006; 19-year follow-up, Rivkin 2015). Computer model: no sustained structural difference at 15 years by start age or frequency (Rahman 2025, in silico). Toxin-related muscle atrophy is temporary and reversible (Durand 2016). Neutralizing antibodies in 3 of 810 glabellar trial subjects (pooled analysis, Toxins 2023). BOTOX Cosmetic label: adults, moderate to severe lines; glabellar trials enrolled ages 18 to 75, mean 46; safety and effectiveness not established in pediatric patients. Body dysmorphic disorder: 15.04% of plastic surgery and 12.65% of dermatology patients (Ribeiro 2017). Daily sunscreen: no detectable increase in skin aging over 4.5 years, 24% less aging than discretionary use (Hughes 2013).
For clinicians: courses, the Complication and Emergency Protocol Pack, and imaging teaching at mccannmd.com. For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. Medhora S. Why more Gen Zs are getting cosmetic injectables such as Botox. ABC News (Australia), February 28, 2026. https://www.abc.net.au/news/2026-02-28/gen-z-driving-boost-cosmetic-injectables/106258646
2. American Society of Plastic Surgeons. 2024 Procedural Statistics: Cosmetic procedures, ages 20 to 29. https://www.plasticsurgery.org/documents/news/statistics/2024/cosmetic-procedures-ages-20-29-2024.pdf
3. American Society of Plastic Surgeons. 2024 Plastic Surgery Statistics Report. https://www.plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf
4. Rothchild E, Jung G, Wang F, Ricci JA. Prejuvenation: what social media tells us about the rising trend. Aesthet Surg J. 2024;44(4):436-443. https://doi.org/10.1093/asj/sjad347
5. Binder WJ. Long-term effects of botulinum toxin type A (Botox) on facial lines: a comparison in identical twins. Arch Facial Plast Surg. 2006;8(6):426-431. https://doi.org/10.1001/archfaci.8.6.426
6. Rivkin A, Binder WJ. Long-term effects of onabotulinumtoxinA on facial lines: a 19-year experience of identical twins. Dermatol Surg. 2015;41 Suppl 1:S64-S66. https://doi.org/10.1097/DSS.0000000000000193
7. Rahman E, Webb WR, Michon A, et al. A 15-year computational twin modeling study of botulinum toxin A frequency and age-related facial aging. Aesthetic Plast Surg. 2026;50(7):2696-2713. https://doi.org/10.1007/s00266-025-05497-1
8. Durand PD, Couto RA, Isakov R, et al. Botulinum toxin and muscle atrophy: a wanted or unwanted effect. Aesthet Surg J. 2016;36(4):482-487. https://doi.org/10.1093/asj/sjv208
9. Pooled immunogenicity analysis of onabotulinumtoxinA across 33 clinical trials (AbbVie authors). Toxins, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10224273/
10. BOTOX Cosmetic (onabotulinumtoxinA) prescribing information, revised 10/2024, sections 1, 8.4 and 14.1. https://www.rxabbvie.com/pdf/botox-cosmetic_pi.pdf
11. Ribeiro RVE. Prevalence of body dysmorphic disorder in plastic surgery and dermatology patients: a systematic review with meta-analysis. Aesthetic Plast Surg. 2017;41(4):964-970. https://doi.org/10.1007/s00266-017-0869-0
12. Adler R, Feig JL, Grant-Kels JM. A wrinkle in time: ethical questions in prejuvenation. J Am Acad Dermatol. 2026 (letter, published online September 7, 2026). https://doi.org/10.1016/j.jaad.2026.08.118
13. Hughes MC, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med. 2013;158(11):781-790. https://doi.org/10.7326/0003-4819-158-11-201306040-00002
Retinol, retinal, adapalene and tretinoin are one family, but they are not interchangeable. Dr. Tom McCann and Nova, his AI co-host, explain the conversion ladder from retinyl esters to retinoic acid, how much strength is lost at each step, what the trials show for acne versus photoaging, how over-the-counter adapalene compares with prescription tretinoin, how to start without irritation, and what to know about pregnancy.
Key facts. Retinyl esters convert to retinol, then retinal (retinaldehyde), then retinoic acid (tretinoin). About 0.25% retinol produced cellular changes similar to 0.025% retinoic acid without redness (Duell 1997). 0.4% retinol reduced fine wrinkles in subjects with a mean age of 87 (Kafi 2007). 0.05% retinaldehyde reduced wrinkles comparably to 0.05% tretinoin at 18 weeks, with less irritation (Creidi 1998). 0.05% tretinoin improved photodamage in 79% vs 48% on vehicle (251 subjects, Weinstein 1991). Adapalene 0.1% gel matched tretinoin 0.025% gel for acne with better tolerability (meta-analysis, 900 patients). Adapalene 0.3% gel was non-inferior to tretinoin 0.05% cream for photoaging (Bagatin 2018). First-trimester topical tretinoin was not associated with increased birth defects in 106 exposed pregnancies (Loureiro 2005).
For clinicians: courses, the Complication and Emergency Protocol Pack, and imaging teaching at mccannmd.com. For patients: text the Artemis office at (833) 387-2996 or leave your info on the Artemis Modern Aesthetics website for a callback.
Join the waitlist for the aesthetic ultrasound injector course: https://artemis-modern-aesthetics.kit.com/dae19ec596
The voices in this episode were generated with AI using ElevenLabs. Tom reviews every script.
This episode is education, not medical advice for any individual.
References
1. Duell EA, Kang S, Voorhees JJ. Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid. J Invest Dermatol. 1997;109(3):301-305. https://doi.org/10.1111/1523-1747.ep12335788
2. Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-348. https://doi.org/10.2147/ciia.2006.1.4.327
3. Weiss JS, Ellis CN, Headington JT, et al. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study. JAMA. 1988;259(4):527-532. PMID 3336176. https://pubmed.ncbi.nlm.nih.gov/3336176/
4. Weinstein GD, Nigra TP, Pochi PE, et al. Topical tretinoin for treatment of photodamaged skin: a multicenter study. Arch Dermatol. 1991;127(5):659-665. PMID 2024983. https://pubmed.ncbi.nlm.nih.gov/2024983/
5. Kafi R, Kwak HS, Schumacher WE, et al. Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol. 2007;143(5):606-612. https://doi.org/10.1001/archderm.143.5.606
6. Kong R, Cui Y, Fisher GJ, et al. A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin. J Cosmet Dermatol. 2016;15(1):49-57. https://doi.org/10.1111/jocd.12193
7. Creidi P, Vienne MP, Ochonisky S, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39(6):960-965. https://doi.org/10.1016/s0190-9622(98)70270-1
8. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139 Suppl 52:48-56. https://doi.org/10.1046/j.1365-2133.1998.1390s2048.x
9. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68(4 Suppl):10-19. PMID 11845943. https://pubmed.ncbi.nlm.nih.gov/11845943/
10. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol. 2003;49(1):83-90. https://doi.org/10.1067/mjd.2003.451
11. Bagatin E, Goncalves HS, Sato M, Almeida LMC, Miot HA. Comparable efficacy of adapalene 0.3% gel and tretinoin 0.05% cream as treatment for cutaneous photoaging. Eur J Dermatol. 2018;28(3):343-350. https://doi.org/10.1684/ejd.2018.3320
12. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. https://doi.org/10.1016/j.jaad.2023.12.017
13. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117-121. https://doi.org/10.1002/ajmg.a.30744
14. US Food and Drug Administration. FDA approves Differin Gel 0.1% for over-the-counter use to treat acne (2016). https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm510362.htm
15. Differin (adapalene gel 0.1%) OTC Drug Facts label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020380Orig1s011lbl.pdf
16. Retin-A Micro (tretinoin gel) prescribing information, revised September 2025, section 8.1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020475s029lbl.pdf
17. US Food and Drug Administration. iPLEDGE REMS for isotretinoin. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm094305.htm